엔테카비르 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 4.5%로 성장할 전망이며, 8억 9,000만 달러로 성장이 예측됩니다. 예측 기간 중 성장은 간질환 대책에 대한 대처 증가, 디지털 헬스케어 솔루션 도입 확대, 헬스케어 인프라 개선, 건강보험 적용 확대, 항바이러스제 수요 증가 등에 기인할 것으로 보입니다. 이 기간 주요 동향에는 유전자 검사 통합, 고급 진단 도구 사용, 맞춤형 의료 진보, 병용 요법 채택, 모니터링 기술의 진보 등이 포함됩니다.
간질환의 유병률 증가는 향후 몇 년간의 엔테카비르 시장의 성장을 견인할 것으로 예측됩니다. 간질환에는 감염병, 유전적 질환, 지방간, 간염, 간경변, 간암 등 생활습관과 관련된 문제 등 간 기능을 해치는 다양한 질환이 포함됩니다. 간질환의 증가는 주로 바이러스성 간염(HBV 및 HCV), 비만율 증가, 알코올 남용, 대사 이상 등의 요인에 의한 것입니다. 항바이러스제인 엔테카비르는 B형 간염 바이러스의 복제를 효과적으로 저해하여 바이러스 양을 감소시키고 간 기능을 개선하며, 간경변이나 간암의 위험을 감소시킴으로써 간질환 환자를 지원합니다. 이것은 최종적으로 만성 B형 간염 감염의 관리와 추가적인 간 장애의 예방에 도움이 됩니다. 예를 들어 2024년 6월 빅토리아주 암평의회는 2022년에 617명이 간암 진단을 받았고, 그 67.9%가 남성이었다고 보고했습니다. 게다가 간 재단은, 연간 약 3,000명이 간세포암(HCC)으로 진단될 것으로 예측하고 있습니다. 따라서 간 질환의 이환율 상승이 엔테카비르 시장의 성장을 촉진하고 있습니다.
B형 간염 증가도 엔테카비르 시장을 밀어 올릴 것으로 예상되고 있습니다. B형 간염은 간을 무릅쓰고 황달, 피로, 복통 등의 증상을 일으키는 바이러스 감염증입니다. 치료되지 않은 경우 만성 간 질환이나 간암으로 이어질 가능성이 있습니다. B형 간염 환자의 증가는 무방비한 성적 접촉, 주삿바늘 공유, 출산 시 모자 감염, 특정 지역에서의 불충분한 백신 접종률 등의 요인과 관련되어 있습니다. 엔테카비르는 B형 간염 바이러스(HBV) DNA의 복제를 저해하고 바이러스 양을 감소시키며 간장애를 예방함으로써 B형 간염을 치료합니다. 예를 들어 2025년 1월 영국 건강안보청은 2022년 영국에서 약 27만 명이 B형 간염에 감염됐으며, 진단된 환자 수는 2030년까지 두 배로 늘어날 것으로 예측하고 있다고 보고했습니다. 그 결과 B형 간염 유병률 증가가 엔테카비르 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 엔테카비르 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 엔테카비르 시장 : 성장률 분석
- 세계의 엔테카비르 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 엔테카비르 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 엔테카비르 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 엔테카비르 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 태블릿
- 경구용액
- 세계의 엔테카비르 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- B형 간염 치료
- 간 이식
- 기타 용도
- 세계의 엔테카비르 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 엔테카비르 시장 : 정제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 표준 용량 정제
- 고용량 정제
- 세계의 엔테카비르 시장 : 경구액별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 즉시 사용할 수 있는 액체 용액
- 경구용액용 분말
제7장 지역별 및 국가별 분석
- 세계의 엔테카비르 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 엔테카비르 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 엔테카비르 시장 : 경쟁 구도
- 엔테카비르 시장 : 기업 프로파일
- Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
- GSK plc 개요, 제품 및 서비스, 전략 및 재무 분석
- Teva Pharmaceutical Industries Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Qingfeng Pharmaceutical Group 개요, 제품 및 서비스, 전략 및 재무 분석
- Aurobindo Pharma Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- ScinoPharm Taiwan Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cipla Inc.
- Zhejiang Huahai Pharmaceuticals Co. Ltd.
- Qianjin Group
- Genix Pharma Ltd.
- Dawnrays Pharmaceutical Holidings Ltd.
- Zhejiang Ausun Pharmaceutical Co. Ltd.
- Hunan Warrant Chiral Pharmaceutical Co. Ltd.
- Camber Pharmaceuticals Inc.
- Century Pharmaceuticals Ltd.
- Aligos Therapeutics Inc.
- HRV Global Life Sceince
- Solco Healthcare LLC
- Accela ChemBio Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 엔테카비르 시장(2029년) : 새로운 기회를 제공하는 국가
- 엔테카비르 시장(2029년) : 새로운 기회를 제공하는 부문
- 엔테카비르 시장(2029년) : 성장 전략
제36장 부록
AJY
Entecavir is an antiviral medication used for the treatment of chronic hepatitis B. It works by inhibiting the replication of the hepatitis B virus, which helps lower the viral load. This, in turn, reduces the risk of severe liver damage and complications such as cirrhosis or liver cancer.
The primary forms of entecavir are tablets and oral solution. Entecavir tablets are taken orally and are prescribed for managing chronic hepatitis B (CHB) infection. These tablets are utilized for a range of purposes, including hepatitis B treatment, liver transplantation, and other related conditions. They are available through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.
The entecavir market research report is one of a series of new reports from The Business Research Company that provides entecavir market statistics, including the entecavir industry's global market size, regional shares, competitors with an entecavir market share, detailed entecavir market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. This entecavir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The entecavir market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.75 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth during the historical period can be attributed to several factors, including the increase in the incidence of hepatitis B, greater awareness of liver-related diseases, a growing emphasis on personalized medicine, the rise of online shopping for medications, and the improved availability of entecavir.
The entecavir market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth during the forecast period can be attributed to increasing efforts to combat liver diseases, a rising adoption of digital healthcare solutions, improvements in healthcare infrastructure, greater health insurance coverage, and a growing demand for antiviral medications. Key trends during this period include the integration of genetic testing, the use of advanced diagnostic tools, advancements in personalized medicine, the adoption of combination therapies, and progress in monitoring techniques.
The increasing prevalence of liver diseases is expected to drive the growth of the entecavir market in the coming years. Liver diseases encompass a variety of conditions that impair liver function, including infections, genetic disorders, and lifestyle-related issues such as fatty liver, hepatitis, cirrhosis, and liver cancer. The rise in liver diseases is primarily attributed to factors such as viral hepatitis (HBV and HCV), increasing obesity rates, alcohol abuse, and metabolic disorders. Entecavir, an antiviral drug, supports liver disease patients by effectively inhibiting the replication of the hepatitis B virus, reducing viral load, improving liver function, and lowering the risk of cirrhosis and liver cancer. This ultimately helps manage chronic hepatitis B infections and prevents further liver damage. For example, in June 2024, the Cancer Council Victoria reported that 617 individuals were diagnosed with liver cancer in 2022, with 67.9% of cases affecting males. Additionally, the Liver Foundation projected that around 3,000 people are diagnosed with hepatocellular carcinoma (HCC) annually. Therefore, the rising incidence of liver diseases is driving the growth of the entecavir market.
The increasing prevalence of hepatitis B is also expected to boost the entecavir market. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain. If untreated, it can lead to chronic liver disease or liver cancer. The rise in hepatitis B cases is linked to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Entecavir treats hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, reducing viral load, and preventing liver damage. For instance, in January 2025, the UK Health Security Agency reported that approximately 270,000 people in the UK were living with hepatitis B in 2022, and the number of diagnosed cases is expected to double by 2030. Consequently, the growing prevalence of hepatitis B is driving the growth of the entecavir market.
Companies in the entecavir market are advancing clinical trials and innovative drug development for chronic hepatitis B treatment, aiming to improve efficacy and treatment outcomes while reducing resistance and enhancing long-term viral suppression. Clinical trials are essential for evaluating the safety and effectiveness of new treatments. For example, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company, initiated a phase 2 clinical trial for ALG-000184, a capsid assembly modulator being developed for hepatitis B treatment. ALG-000184 works by disrupting the formation of the capsid, the protective shell around a virus's genetic material. The ongoing study is assessing the long-term effects of ALG-000184, either alone or in combination with entecavir (sold as Baraclude), in patients with chronic hepatitis B. Preliminary results indicate that the combination of ALG-000184 and entecavir led to more significant reductions in viral load compared to entecavir alone, with ALG-000184 maintaining similar effectiveness regardless of its use alongside entecavir. The virus remained suppressed throughout the study in both HBeAg-positive and HBeAg-negative patients.
Major players in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc., HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.
Asia-Pacific was the largest region in the entecavir market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in entecavir report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Entecavir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Entecavir Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on entecavir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for entecavir ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The entecavir market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Type: Tablets; Oral Solution
- 2) By Application: Hepatitis B Treatment; Liver Transplantation; Other Applications
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Tablets: Standard Dose Tablets; High Dose Tablets
- 2) By Oral Solution: Ready-to-Use Liquid Solution; Powder For Oral Solution
- Companies Mentioned: Bristol-Myers Squibb Company; GSK plc; Teva Pharmaceutical Industries Ltd.; Qingfeng Pharmaceutical Group; Aurobindo Pharma Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Entecavir Market Characteristics
3. Entecavir Market Trends And Strategies
4. Entecavir Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Entecavir Growth Analysis And Strategic Analysis Framework
- 5.1. Global Entecavir PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Entecavir Market Growth Rate Analysis
- 5.4. Global Entecavir Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Entecavir Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Entecavir Total Addressable Market (TAM)
6. Entecavir Market Segmentation
- 6.1. Global Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tablets
- Oral Solution
- 6.2. Global Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatitis B Treatment
- Liver Transplantation
- Other Applications
- 6.3. Global Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Entecavir Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Standard Dose Tablets
- High Dose Tablets
- 6.5. Global Entecavir Market, Sub-Segmentation Of Oral Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ready-to-Use Liquid Solution
- Powder For Oral Solution
7. Entecavir Market Regional And Country Analysis
- 7.1. Global Entecavir Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Entecavir Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Entecavir Market
- 8.1. Asia-Pacific Entecavir Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Entecavir Market
- 9.1. China Entecavir Market Overview
- 9.2. China Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Entecavir Market
- 10.1. India Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Entecavir Market
- 11.1. Japan Entecavir Market Overview
- 11.2. Japan Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Entecavir Market
- 12.1. Australia Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Entecavir Market
- 13.1. Indonesia Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Entecavir Market
- 14.1. South Korea Entecavir Market Overview
- 14.2. South Korea Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Entecavir Market
- 15.1. Western Europe Entecavir Market Overview
- 15.2. Western Europe Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Entecavir Market
- 16.1. UK Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Entecavir Market
- 17.1. Germany Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Entecavir Market
- 18.1. France Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Entecavir Market
- 19.1. Italy Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Entecavir Market
- 20.1. Spain Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Entecavir Market
- 21.1. Eastern Europe Entecavir Market Overview
- 21.2. Eastern Europe Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Entecavir Market
- 22.1. Russia Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Entecavir Market
- 23.1. North America Entecavir Market Overview
- 23.2. North America Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Entecavir Market
- 24.1. USA Entecavir Market Overview
- 24.2. USA Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Entecavir Market
- 25.1. Canada Entecavir Market Overview
- 25.2. Canada Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Entecavir Market
- 26.1. South America Entecavir Market Overview
- 26.2. South America Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Entecavir Market
- 27.1. Brazil Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Entecavir Market
- 28.1. Middle East Entecavir Market Overview
- 28.2. Middle East Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Entecavir Market
- 29.1. Africa Entecavir Market Overview
- 29.2. Africa Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Entecavir Market Competitive Landscape And Company Profiles
- 30.1. Entecavir Market Competitive Landscape
- 30.2. Entecavir Market Company Profiles
- 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Qingfeng Pharmaceutical Group Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Entecavir Market Other Major And Innovative Companies
- 31.1. ScinoPharm Taiwan Ltd.
- 31.2. Dr. Reddy's Laboratories Ltd.
- 31.3. Cipla Inc.
- 31.4. Zhejiang Huahai Pharmaceuticals Co. Ltd.
- 31.5. Qianjin Group
- 31.6. Genix Pharma Ltd.
- 31.7. Dawnrays Pharmaceutical Holidings Ltd.
- 31.8. Zhejiang Ausun Pharmaceutical Co. Ltd.
- 31.9. Hunan Warrant Chiral Pharmaceutical Co. Ltd.
- 31.10. Camber Pharmaceuticals Inc.
- 31.11. Century Pharmaceuticals Ltd.
- 31.12. Aligos Therapeutics Inc.
- 31.13. HRV Global Life Sceince
- 31.14. Solco Healthcare LLC
- 31.15. Accela ChemBio Inc.
32. Global Entecavir Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Entecavir Market
34. Recent Developments In The Entecavir Market
35. Entecavir Market High Potential Countries, Segments and Strategies
- 35.1 Entecavir Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Entecavir Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Entecavir Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
